Vmbook Online ordering

Galectin Therapeutics Inc

Galectin Therapeutics, Inc. is a publicly-traded company listed on the NASDAQ stock exchange under the ticker symbol GALT. It is a clinical-stage biopharmaceutical company based in Nevada, USA. The company focuses on developing drugs to treat fibrosis, inflammation, and cancer.

Galectin Therapeutics was founded in 2000 and has since developed a pipeline of drug candidates, including its lead product candidate, belapectin (formerly known as GR-MD-02). The company has conducted clinical trials for belapectin in patients with non-alcoholic steatohepatitis (NASH), a type of liver disease, with promising results.

Galectin Therapeutics has also explored the use of belapectin in treating other conditions, such as cancer and cardiovascular disease. The company has been successful in raising funds through equity offerings and collaboration agreements with external partners.

As a publicly-traded company, Galectin Therapeutics is subject to reporting and regulatory requirements set by the Securities and Exchange Commission (SEC) and must file periodic reports disclosing its financial performance, operations, and risk factors.

Investors and analysts can access this information through the SEC's Edgar database or the company's website. Overall, Galectin Therapeutics is a biotech company focused on developing innovative treatments for various diseases, and its public listing allows it to access capital markets to fund its research and development activities.